TY - JOUR
T1 - Quality and Safety Considerations in Image Guided Radiation Therapy
T2 - An ASTRO Safety White Paper Update
AU - Qi, X. Sharon
AU - Albuquerque, Kevin
AU - Bailey, Stephanie
AU - Dawes, Samantha
AU - Kashani, Rojano
AU - Li, Heng
AU - Mak, Raymond H.
AU - Mundt, Arno J.
AU - Sio, Terence T.
N1 - Funding Information:
Source of support: This work was funded by the Amercian Society for Radiation Oncology. Disclosures: All task force members’ disclosure statements were reviewed before being invited and were shared with other task force members throughout the document's development. Those disclosures are published within this report. Where potential conflicts were detected, remedial measures to address them were taken. Dr Albuquerque reports surveyor travel expenses and honoraria from the American College of Radiology, committee member travel expenses and honoraria from the American Registry of Radiologic Technologists, committee member travel expenses from the American Society of Clinical Oncology, and research grants from AstraZeneca. Dr Kashani is a task force representative for the American Association of Physicists in Medicine. Dr Mak is on an advisory board for AstraZeneca and reports honoraria and travel expenses from NewRT and research grants, honoraria, and advisory board membership from ViewRay. Dr Mundt reports honoraria from UpToDate, US Oncology (Ask The Expert website), and Varian Medical Systems. Dr Qi reports honoraria from Accuray Inc, and research grants and honoraria from Varian Medical Systems. Dr Sio is part of the speakers’ bureau and advisory board for Novocure and the advisory board for Galera Therapeutics. No other disclosures were reported.
Funding Information:
Disclosures: All task force members’ disclosure statements were reviewed before being invited and were shared with other task force members throughout the document's development. Those disclosures are published within this report. Where potential conflicts were detected, remedial measures to address them were taken. Dr Albuquerque reports surveyor travel expenses and honoraria from the American College of Radiology, committee member travel expenses and honoraria from the American Registry of Radiologic Technologists, committee member travel expenses from the American Society of Clinical Oncology, and research grants from AstraZeneca. Dr Kashani is a task force representative for the American Association of Physicists in Medicine. Dr Mak is on an advisory board for AstraZeneca and reports honoraria and travel expenses from NewRT and research grants, honoraria, and advisory board membership from ViewRay. Dr Mundt reports honoraria from UpToDate, US Oncology (Ask The Expert website), and Varian Medical Systems. Dr Qi reports honoraria from Accuray Inc, and research grants and honoraria from Varian Medical Systems. Dr Sio is part of the speakers’ bureau and advisory board for Novocure and the advisory board for Galera Therapeutics. No other disclosures were reported.
Funding Information:
Source of support: This work was funded by the Amercian Society for Radiation Oncology.
Publisher Copyright:
© 2022 American Society for Radiation Oncology
PY - 2023/3/1
Y1 - 2023/3/1
N2 - Purpose: This updated report on image guided radiation therapy (IGRT) is part of a series of consensus-based white papers previously published by the American Society for Radiation Oncology addressing patient safety. Since the first white papers were published, IGRT technology and procedures have progressed significantly such that these procedures are now more commonly used. The use of IGRT has now extended beyond high-precision treatments, such as stereotactic radiosurgery and stereotactic body radiation therapy, and into routine clinical practice for many treatment techniques and anatomic sites. Therefore, quality and patient safety considerations for these techniques remain an important area of focus. Methods and Materials: The American Society for Radiation Oncology convened an interdisciplinary task force to assess the original IGRT white paper and update content where appropriate. Recommendations were created using a consensus-building methodology, and task force members indicated their level of agreement based on a 5-point Likert scale from “strongly agree” to “strongly disagree.” A prespecified threshold of ≥75% of raters who selected “strongly agree” or “agree” indicated consensus. This IGRT white paper builds on the previous version and uses other guidance documents to primarily focus on processes related to quality and safety. IGRT requires an interdisciplinary team-based approach, staffed by appropriately trained specialists, as well as significant personnel resources, specialized technology, and implementation time. A thorough feasibility analysis of resources is required to achieve the clinical and technical goals and should be discussed with all personnel before undertaking new imaging techniques. A comprehensive quality-assurance program must be developed, using established guidance, to ensure IGRT is performed in a safe and effective manner. As IGRT technologies continue to improve or emerge, existing practice guidelines should be reviewed or updated regularly according to the latest American Association of Physicists in Medicine Task Group reports or guidelines. Patient safety in the application of IGRT is everyone's responsibility, and professional organizations, regulators, vendors, and end-users must demonstrate a clear commitment to working together to ensure the highest levels of safety.
AB - Purpose: This updated report on image guided radiation therapy (IGRT) is part of a series of consensus-based white papers previously published by the American Society for Radiation Oncology addressing patient safety. Since the first white papers were published, IGRT technology and procedures have progressed significantly such that these procedures are now more commonly used. The use of IGRT has now extended beyond high-precision treatments, such as stereotactic radiosurgery and stereotactic body radiation therapy, and into routine clinical practice for many treatment techniques and anatomic sites. Therefore, quality and patient safety considerations for these techniques remain an important area of focus. Methods and Materials: The American Society for Radiation Oncology convened an interdisciplinary task force to assess the original IGRT white paper and update content where appropriate. Recommendations were created using a consensus-building methodology, and task force members indicated their level of agreement based on a 5-point Likert scale from “strongly agree” to “strongly disagree.” A prespecified threshold of ≥75% of raters who selected “strongly agree” or “agree” indicated consensus. This IGRT white paper builds on the previous version and uses other guidance documents to primarily focus on processes related to quality and safety. IGRT requires an interdisciplinary team-based approach, staffed by appropriately trained specialists, as well as significant personnel resources, specialized technology, and implementation time. A thorough feasibility analysis of resources is required to achieve the clinical and technical goals and should be discussed with all personnel before undertaking new imaging techniques. A comprehensive quality-assurance program must be developed, using established guidance, to ensure IGRT is performed in a safe and effective manner. As IGRT technologies continue to improve or emerge, existing practice guidelines should be reviewed or updated regularly according to the latest American Association of Physicists in Medicine Task Group reports or guidelines. Patient safety in the application of IGRT is everyone's responsibility, and professional organizations, regulators, vendors, and end-users must demonstrate a clear commitment to working together to ensure the highest levels of safety.
UR - http://www.scopus.com/inward/record.url?scp=85148332198&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85148332198&partnerID=8YFLogxK
U2 - 10.1016/j.prro.2022.09.004
DO - 10.1016/j.prro.2022.09.004
M3 - Article
C2 - 36585312
AN - SCOPUS:85148332198
SN - 1879-8500
VL - 13
SP - 97
EP - 111
JO - Practical Radiation Oncology
JF - Practical Radiation Oncology
IS - 2
ER -